Advertisement
"The implementation of our quality management system has established asolid foundation that will facilitate regulatory approval of our products on aglobal basis," said K. Wayne Marshall, MD, PhD, President and Chief ExecutiveOfficer of GeneNews. "This ISO accreditation reflects our commitment toquality and is an important milestone in the commercialization strategy forour products."
Advertisement
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enableearly diagnosis and personalized therapeutic intervention based ondisease-specific biomarkers. The Company has developed a novel approach, theSentinel Principle(TM), to detect and stage virtually any disease or medicalcondition from a simple blood sample. GeneNews is currently applying theSentinel Principle in major areas with unmet clinical needs such as cancer,arthritis, cardiovascular disease and neurological disorders. GeneNews' firstproduct in development, ColonSentry, is a convenient and patient-friendlyblood-based biomarker test that can identify the current risk of colorectalcancer. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect theCompany's current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual events could differmaterially from those projected herein. Investors should consult the Company'songoing quarterly filings and annual reports for additional information onrisks and uncertainties relating to these forward-looking statements. Thereader is cautioned not to rely on these forward-looking statements. TheCompany disclaims any obligation to update these forward-looking statements.
SOURCE GeneNews Limited
